Biliary atresia therapeutics market seen reaching $1.53 billion by 2030

The Business Research Company says the global biliary atresia therapeutics market will rise from $1.02 billion in 2025 to $1.53 billion by 2030 as newborn screening, rare-disease investment and pediatric liver care expand. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Biliary atresia is a rare infant liver disease, so faster diagnosis and better treatment access can change outcomes early in life. - The market’s projected climb to $1.53 billion by 2030 points to rising demand for therapies, surgery, screening and long-term pediatric liver care. - The report highlights a growing commercial focus on rare diseases, where screening programs and specialized care can create measurable demand.

What happened: - The Business Research Company published a biliary atresia therapeutics market report covering 2026-2035. - The report estimates the market at $1.02 billion in 2025 and $1.11 billion in 2026. - The report projects the market will reach $1.53 billion by 2030, implying an 8.5% compound annual growth rate from 2026 to 2030. - North America was the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - A free sample of the report is available. - The full report is also available.

The details: - Biliary atresia therapeutics include pharmaceutical and medical treatments used to manage blocked or absent bile ducts in infants. - The therapies are intended to improve bile flow, reduce liver damage, address complications and support overall liver function. - Historic growth from 2025 to 2026 is tied to greater awareness of pediatric liver disease, improved kasai portoenterostomy outcomes, expanded pediatric hepatology services, wider liver transplant availability and better nutritional support. - Future growth is expected to come from novel therapies that improve bile flow, more personalized medicine, specialized pediatric care facilities, higher rare-disease investment and surgical advances. - Key trends in the market include minimally invasive biliary surgery, early diagnosis and intervention, combination drug therapies, expanded pediatric liver transplantation and more postoperative and long-term disease management. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - Expansion in newborn screening is a major demand driver because earlier diagnosis can push more infants into treatment pathways sooner. - The UK National Screening Committee opened a consultation in March 2026 on newborn screening for biliary atresia. - The disease affects about 1 in 17,000 babies in the UK, and early treatment within two months is critical for better outcomes. - Population-wide screening is still under evaluation, so the market boost from screening depends on how broadly programs are adopted. - The projected regional split suggests mature demand in North America and faster adoption potential in Asia-Pacific as pediatric care capacity expands.

What's next: - Adoption of neonatal screening programs could increase the number of diagnosed patients moving into treatment earlier. - More minimally invasive surgery, combination therapies and transplant programs are likely to shape the market through 2030. - Specialized pediatric facilities and rare-disease investment should remain key watch points for providers, investors and drug developers. - The company says the 2026 report set includes enhanced strategic insights, updated graphics and forecasting tools for market tracking.

The bottom line: - Biliary atresia therapeutics is still a niche market, but earlier diagnosis, better pediatric care and rare-disease investment are pushing it into a steady growth phase.